The underlying mechanism for the improvement in PFS is likely multifactorial, involving not only the direct antitumor effects of PD-1/PD-L1 blockade but also the modulation of the tumor microenvironment and the promotion of a more effective and sustained antitumor immune response. Here, PDCD1 is linked to neoplasm.